Zobrazeno 101 - 110
of 426
pro vyhledávání: ''
Autor:
Paul H. Mason, Phuong Thuy Tran, Ben J. Marais, Steve Graham, David W. Dowdy, Marcel A. Behr, Warwick J. Britton, Guy B. Marks, Kavi Velen, Andrea Benedetti, Dick Menzies, Cam Binh Nguyen, Viet Nhung Nguyen, Binh Hoa Nguyen, Thu Anh Nguyen, Greg J. Fox
Publikováno v:
BMJ Open
IntroductionTreatment of latent tuberculosis infection (LTBI) plays a substantial role in the prevention of drug-susceptible tuberculosis (TB). However, clinical trials to evaluate the efficacy of preventive therapy for presumed multidrug-resistant (
Publikováno v:
BMJ Open
IntroductionHerpes simplex labialis (HSL) is a common infection that can cause painful lesions on the oral mucosa, commonly referred to as cold sores. Current biomedical treatments include topical aciclovir, which reduces the episode duration by an a
Publikováno v:
BMJ Open
IntroductionCisplatin (CDDP) is a key drug for various thoracic malignancies. To avoid renal toxicity of CDDP, mannitol is routinely used, but it sometimes causes phlebitis which damages patients’ quality of life. Furosemide is another widely used
Autor:
Anne V. Grossestreuer, Michael W. Donnino, Lars W. Andersen, Ari Moskowitz, David T. Huang, Tuyen Yankama
Publikováno v:
Moskowitz, A, Yankama, T, Andersen, L W, Huang, D T, Donnino, M W, Grossestreuer, A V & ACTS Clinical Trial Investigators 2019, ' Ascorbic Acid, Corticosteroids and Thiamine in Sepsis (ACTS) protocol and statistical analysis plan : a prospective, multicentre, double-blind, randomised, placebo-controlled clinical trial ', BMJ Open, vol. 9, no. 12, e034406 . https://doi.org/10.1136/bmjopen-2019-034406
BMJ Open
BMJ Open
IntroductionSeptic shock is a common and highly morbid condition. To date, there is no specific therapy proven to attenuate organ injury in septic shock. Recent studies have suggested a role for the combination of ascorbic acid, corticosteroids and t
Autor:
Ji'e Yang, Junbo Ge, Ruifen Cao, Ming Zheng, Yuxiang Dai, Chenguang Li, Hongbo Yang, Feng Zhang, Juying Qian, Kang Yao
Publikováno v:
BMJ Open
IntroductionDual antiplatelet therapy (DAPT) with aspirin and thienopyridine is required after placement of coronary stents to prevent thrombotic complications. However, current recommendation for duration of DAPT remains controversial. Firehawk is a
Publikováno v:
BMJ Open
ObjectivesAlthough the smoking prevalence continues to decline in New Zealand (NZ) overall, little is known about smoking in university students. A 2013 survey of students aged 17–25 years found that 14% were current smokers, and 3% daily smokers.
Publikováno v:
BMJ Open
Mitchell, A, Welsh, T J, Watson, M C, Snowball, J & McGrogan, A 2019, ' Use of oral anticoagulants in older people with atrial fibrillation in UK general practice : protocol for a cohort study using the Clinical Practice Research Datalink (CPRD) database ', BMJ Open, vol. 9, no. 12, e032646 . https://doi.org/10.1136/bmjopen-2019-032646
Mitchell, A, Welsh, T J, Watson, M C, Snowball, J & McGrogan, A 2019, ' Use of oral anticoagulants in older people with atrial fibrillation in UK general practice : protocol for a cohort study using the Clinical Practice Research Datalink (CPRD) database ', BMJ Open, vol. 9, no. 12, e032646 . https://doi.org/10.1136/bmjopen-2019-032646
IntroductionWarfarin has frequently been underused in older people for stroke prevention in atrial fibrillation (AF). Direct oral anticoagulants (DOACs) entered the UK market from 2008 and have been recommended as an alternative to warfarin. This stu
Autor:
Ying Qin, Jie Han, Zhihui Zhu, Kun Liu, Yuehuan Li, Yan Li, Jinglun Shen, Xu Meng, Haibo Zhang
Publikováno v:
BMJ Open
IntroductionWarfarin is an effective anticoagulant and the only oral anticoagulant available for patients with mechanical heart valves. The prothrombin time and the associated international normalised ratio (INR) are routinely tested to monitor the r
Autor:
Esther van Meerten, Ruben A G van Eerden, Alexander Constantinides, Alexandra R. M. Brandt-Kerkhof, Femke M. de Man, Geert Jan Creemers, Stijn L.W. Koolen, Checca Bakkers, Onno Kranenburg, Eva V. E. Madsen, Maarten J. Deenen, Nadine L. de Boer, Ignace H. J. T. de Hingh, Ron H.J. Mathijssen, Marjolein Diepeveen, Rachida Bouamar, Jacobus W. A. Burger, Cornelis Verhoef, Koen P. Rovers
Publikováno v:
BMJ Open, 9(12), e034508. BMJ Publishing Group
BMJ Open, 9(12):e034508. BMJ Publishing Group
BMJ Open
BMJ Open, 9(12):e034508. BMJ Publishing Group
BMJ Open
IntroductionCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has become standard of care for patients with peritoneal metastases of colorectal origin with a low/moderate abdominal disease load. In case of a peritoneal c
Autor:
Piergiorgio Messa, Antonello Pani, Francesco Scolari, Loreto Gesualdo, Riccardo Magistroni, Marisa Santostefano, Giuliano Boscutti, Domenico Santoro, Marco Quaglia, Nadia Dallera, Pietro Ravani, Sandro Feriozzi, Laila Yasmin Mani, Claudio Ponticelli
Publikováno v:
BMJ Open
Scolari, Francesco; Dallera, Nadia; Gesualdo, Loreto; Santoro, Domenico; Pani, Antonello; Santostefano, Marisa; Feriozzi, Sandro; Mani, Laila-Yasmin; Boscutti, Giuliano; Messa, Piergiorgio; Magistroni, Riccardo; Quaglia, Marco; Ponticelli, Claudio; Ravani, Pietro (2019). Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ open, 9(12), e029232. BMJ Publishing Group 10.1136/bmjopen-2019-029232
Scolari, Francesco; Dallera, Nadia; Gesualdo, Loreto; Santoro, Domenico; Pani, Antonello; Santostefano, Marisa; Feriozzi, Sandro; Mani, Laila-Yasmin; Boscutti, Giuliano; Messa, Piergiorgio; Magistroni, Riccardo; Quaglia, Marco; Ponticelli, Claudio; Ravani, Pietro (2019). Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ open, 9(12), e029232. BMJ Publishing Group 10.1136/bmjopen-2019-029232
IntroductionPrimary membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. The disease may have different long-term outcomes. After 10 years of follow-up, 35%–50% of the untreated patients with persistent nephrotic syndrome